← Eichor
Study identifier: NCT06630923 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

PREVENTION OF WORSENING RENAL FUNCTION OF INTRAVENUS ALBUMIN IN HEART FAILURE PATIENTS

Condition: Diuretics Drug Reactions · Heart Failure; With Decompensation · Albumin; Double  ·  Sponsor: Democritus University of Thrace

PhasePhase 3
Planned participants250
Who can joinAll sexes, 18 Years to 95 Years
Healthy volunteersNo

About this study

Patients hospitalized for acute decompensation of CHF are usually complicated by worsening renal function (WRF) which leads to diuretic resistance and inadequate decongestion as well as poor prognosis. WRF has been attributed to a reflex renal vasoconstriction elicited by intravascular volume depletion during brisk diuresis. The investigators hypothesize that CHF patients with hepatic dysfunction are more prone to WRF due to poor albumin production. This sub-group of CHF patients may benefit more (increased diuretic efficacy and protected against worsening renal function) by the use of IV loop diuretics in combination with an intravascular volume expander such as IV Human Albumin.

This description comes directly from the study's public registry record.

Talk to the study team

MARIOS-VASILEIOS A KOUTROULOS  ·  +30 6942862493  ·  mvkoutroulos@gmail.com

ANARGYROS TSALGKIDIS  ·  6940926983  ·  anargyrost@gmail.com

Always discuss trial participation with your own doctor first.

Locations (1)

DUThrace Cardiology DepartmentAlexandroupoli, Evros, GreeceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06630923